Ionis Pharmaceuticals Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California. GBP drops as BOE vote split seems dovishThe BOE has left rates unchanged in December but a more dovish vote split has weighed on the pound.
13:07, 19 December 2024
A hawkish Fed cut sparks fresh volatilityDiscover how the Federal Reserve's hawkish stance, revised SEP, and delayed inflation targets triggered market volatility, with stocks tumbling, bond yields surging, and a stronger US Dollar reshaping investor outlooks.
12:58, 19 December 2024
Gold Latest: XAU/USD stuck within range ahead of the FOMC meetingGold traders await the FOMC meeting to determine how many rate cuts to expect in 2025.
11:17, 18 December 2024
GBP/USD in focus ahead of FED and BOE meetings Both the Federal Reserve and Bank of England will deliver their updated monetary policies this week, with GBP/USD likely to experience increased momentum.
17:16, 17 December 2024